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Abstract  
Introduction: Visceral leishmaniasis (VL) without anemia is very rare, means that 
almost all VL patients have anemia .It occurs due to many factors like sequestration and 
destruction of red blood cells (RBC) in enlarged spleen and bone marrow, immune 
mechanism, and alterations in RBC membrane permeability. 
Objective: The objective of this study is to determine change in hemoglobin and its 
determinant factors among visceral leishmaniasis patients with and without iron–folic 
acid supplementation, in Northwest Ethiopia, 2017. 
Methods: Retrospective cohort  study was conducted by reviewing all VL patients chart 
from Jan /2015 to Dec/2016.Data  was entered to EpiData version 3.1  and transferred 
to Stastical Package for Social Science (SPSS)  version 20 for analysis. The data was 
analyzed using independent sample T test and linear regression model. Ninety five 
percent (95 %) confidence level was used and p-values less than 0.05 considered as 
statistically significant. 
Result: From a total of 602 visceral leishmaniasis patients, 300(49.8%) were from 
University of Gondar hospital and 302(50.2%) Abdurafi MSF Holland treatment centers. 
The mean (SD) change in hemoglobin from baseline to end of VL treatment was 
0.99(±1.64) and1.61 (±1.88) g/dl with and without iron-folate supplementations 
respectively with the P-value of <0.0001at 95% confidence level. In multiple linear 
regression analysis combination of sodium stibogluconate and paramomycine was 
positive predictor variable. Whereas age, nasal bleeding ,baseline white blood cell and 
hemoglobin ,end of treatment spleen size and iron–folic acid supplementation were 
negatively associated with the outcome variable of change of hemoglobin.  
Conclusion and recommendation: The use of Iron-folic acid during the active stage of 
visceral leishmaniasis does not help for the improvement of hemoglobin, rather it 
delays. Probably the leishmania parasite might use it for survival and growth. Therefore 
we recommend for scholars to investigate the appropriate time of iron–folic acid 
supplementation. 
Key words: Anemia, visceral leishmaniasis, Iron-folic acid supplementation and change of hemoglobin 
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1. Introduction   
1.1 Statement of the problem   
Anemia is a condition characterized by decrease in hemoglobin concentration below the 
acceptable range. It is convenient to use the hemoglobin thresholds defined by the 
World Health Organization (WHO) or decrease oxygen-carrying capacity to meet 
physiological needs of the body (1). Anemia is a major global public health problem 
especially in developing countries. The World Health Organization estimates that 
anemia affects nearly two billion people all over the world. This means that one quarter 
of the global population are affected by anemia. Among this, Iron deficiency anemia 
(IDA) is responsible  for  approximately 50% of all types  of anemia and 800, 000 deaths 
per year worldwide(2). Anemia causes physical and mental disability in children and in 
elderly, as well as working capacity reduction in adults. The above  figure indicates that, 
in many countries, anemia constitutes a serious health problem in the population (3). 
Visceral leishmaniasis (VL) is one of the major causes of anemia .It is very serious but 
treatable neglected protozoal parasitic disease. It is potentially fatal and responsible for 
the deaths up to 40,000 people per year worldwide(4). The annual global burden shows, 
approximately 0.2 to 0.4 million VL cases(5). More than 90% of VL cases occur in just 
six countries: Brazil, Ethiopia, India, Bangladesh, South Sudan and Sudan (6). The 
annual incidence of VL in Eastern Africa ranges between 29,400 to 56,700 cases  
accounting for approximately 15 % of the global burden (7). It is the second high 
disease burden next to the Indian subcontinent. Ethiopia is the second largest number 
of VL cases in sub-Saharan Africa with an estimated annual burden of  2,000-4,500 new 
cases  per year (9).  
The burden of VL disproportionately affects on the poorest segments of the global 
population. Poverty is associated with poor nutrition and other infectious diseases, poor 
nutrition increase the risk of infection, and clinically manifested disease (10). In Ethiopia 
more than 93.8 % and 73% of visceral leishmaniasis patients are daily laborer and 
illiterate respectively indicating that the monthly income is very low (11).  
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 Anemia is the most common clinical presentation among VL patients that occur due to 
many factors like sequestration and destruction of red blood cells (RBC) in enlarged 
spleen and bone marrow, immune mechanism, and alterations in RBC membrane 
permeability have been implicated. Red cell survival and ferrokinetic studies have 
suggested that hemolysis is the major cause of anemia in VL. Other conditions like long 
duration of illness, concomitant disease (inflammation), nutritional status and intestinal 
helminthes are also major contributing factor for anemia in visceral leishmaniasis 
patients(12). The clinical presentation of VL varies from region to region reflecting 
differences in parasite strains, vectors, and hosts(6).  
 Nutritional deficiency macro nutrient and micro nutrient) like iron, vitamin B12, and 
folate play great role. The coexistence of these micronutrient deficiencies and iron 
deficiency may causes  anemia (13). The prevalence of anemia among VL patients 
shows more than 90%, and the degree of anemia  is moderate to severe (hemoglobin 
level∼7.5 g/dl), and the status can be recovered with anti-leishmaniasis drug within a 
certain period of time(14). 
Despite the national leishmaniasis treatment guideline recommendation to supplement 
iron and folic acid for the management of anemia(8), there is no VL treatment centers 
has been applied the recommendation except Abdurafi Medicine Sans Frontiers (MSF) 
Holland Kala-azar treatment center. However, there was no clear evidence that shows 
the effect of iron and folic acid regarding to VL patients but there are experimental 
studies indicates iron is crucial for survival and growth of leishmania parasite(15, 16). In 
contrary to this dietary iron has no effect but iron overload suppress the parasite 
replication and makes it attenuated(17).  
Therefore  our study aims was  to answer the question whether iron and folic acid had 
better improvement for anemia among Visceral leishmaniasis patients or not?  
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1.2. Literature Review 
1.2.1. Anemia among Visceral Leishmaniasis  
Norm chromic normocytic anemia is a frequent and clinically signiﬁcant feature of VL 
and in this study the serum iron was measured and found to be  normal(18). However, 
in some studies found erythrocytes in VL patients as microcytic and hypo chromic. This 
could be due to Iron deficiency anemia(19).Another  Prospective study conducted at 
BPKIHS Hospital, Nepal among 50 cases of visceral leishmaniasis 30 of cases showed 
microcytic red cell and hyper segmented neutrophils on peripheral blood smear as 
features of megaloblastic anemia. Among 30 cases of VL with megaloblastic features’ 
15 of them were treated with Sodium Antimony Gluconate (SAG) only and the other 15 
treated with SAG, folic acid and vitamin B12 and the rest 20 cases also treated with 
SAG. After treatment all 50 cases hemoglobin and total lymphocyte count improved .but 
in those patients treated with SAG, folic acid and vitamin B12 the reticulocyte count 
reached peak on the 7th day and normalized at end of 4th week(20).  
Another Study conducted in animal model (hamsters) that shows the level of iron from 
blood was significantly decreased and accumulated in liver. In this study there was no 
significant difference in mean cell volume (MCV) and mean corpuscular hemoglobin 
concentration (MCHC) level between infected and control hamsters(21). 
A systematic review shows that the overall prevalence of anemia is higher than 90 %. 
The degree of anemia in VL is moderate to severe (hemoglobin level ∼7.5 g/dl)(14). A 
case control study conducted in Sudan shows that the mean hemoglobin of the baseline 
and end of treatment (at 30day) was 6.5g/dl and 9.5g/dl respectively. But the serum iron 
and total iron binding capacity (TIBC) were not significantly reduced. (22). Mean 
prevalence of anemia in two studies using hemoglobin (HGB) levels of 11g/dl as cutoffs 
were 98.8 %( range (96.5-100)(23, 24).Other three studies using similar cutoffs 
presented high prevalence of anemia(100%.at <10.5g/dl) and 92%≤10g/dl(25, 26). This 
shows that the prevalence of anemia is very high in VL patients. Whereas six studies 
described the prevalence of anemia with the HGB level ≤9g/dl with the mean of 83.2% 
(range 75-87.9%)(27-31).  
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A retrospective cohort study was conducted among confirmed VL between January 
2000 and December 2005 in Belo Horizonte, Brazil: the mean hemoglobin level was 
9g/dl and 86.8% of the patients were anemic(32). In Northern Italian retrospective 
observational study were conducted from January, 2012 to December 2015 ,among 
16patients anemia was observed in all (100%) patients(33).In Southwestern Iran  
retrospective study was conducted  in this period (1999-2014) among 380 VL patients, 
rate of anemia was   87.3%, 7.5% leucopenia, 39.5% leukocytosis and 64% were 
thrombocytopenia  (34). and another retrospective study conducted in Tehran medical 
hospital ,Iran a total number of 34 children with confirmed VL through 2004-2011  were 
included in the study ,Of the total children  with VL (97.1%) were anemic, 91.2% had  
thrombocytopenia and  (67.6%) leucopenia (35). In a routine VL treatment program in 
Pokot, Uganda,  Medecins Sans Frontieres diagnosed and treated 4,831 patients with 
visceral leishmaniasis (VL) between 2000 and 2010; The retrospective analysis of their 
VL patients data showed that  the mean hemoglobin level of VL patient was 7.9g/dl(12). 
Institutional based cross sectional study conducted in North West Ethiopia which shows 
that among 403 VL patients, 35.6%, 35.1%,42.3% mildly, moderately and severely 
anemic respectively , indicating that more than 95% of the patients had anemia in this 
region (11). 
Retrospective study conducted in Amudat hospital, Uganda and kachilba health center 
in Kenya from 2000-2010;  all clinical presentation were not consistently recorded in 
Amudat, the most frequently reported symptoms in Kacheliba  among 2301 patients in 
addition to fever were  weight loss (87.8%), loss of appetite (86.8%), enlargement of 
spleen  (77.1%), nasal  bleeding (21.9%), vomiting (16.5%)headache (14.6%), 
abdominal pain (13.0%), abdominal swelling (11.4%), and diarrhea (8.5%). On physical 
examination, mean spleen size was 12.3 cm below the costal margin in Amudat and 
11.4 cm in Kachelib. Other objective signs such as pallor, edema, and jaundice were 
reported in respectively= 45.8%, 8%, and 2.3% of cases. More than half of the patients 
were malnourished on admission, with 24.7% severely malnourished and 
27.6%(moderately malnourished(12).(by WHO classification criteria ).` Institutional 
based cross sectional study conducted in Northwest Ethiopia which shows that among 
403 VL patients 29.3% mildly,31.7% moderately and 39% severely malnourished 
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(according to  world health organization (WHO) classification criteria)and nearly half of 
the patients also infected with one or more intestinal parasite ,among this 21% 
accounted hook warm(11).A retrospective study was conducted at a tertiary care centre 
serving the kumaon region of Uttarakhand from 2010 to 2014 Splenomegally was the 
most common sign observed in 17 cases (85%), followed by pallor in 15 cases (75%), 
pyrexia in 14 cases (70%), weight loss in 12 cases (60%), hepatomegally in 8 cases 
(40%) and jaundice in 4 cases (20%). Bleeding manifestations were seen in 2 cases 
(10%)(36).In fact bleeding is risk factor for anemia and finally leads to death among VL 
cases(37). 
1.2.2. Determinant factors 
The cause of anemia is multifactorial: duration of illness, and Size of spleen significantly 
correlate hematological features(38).  Reduced plasma iron level in the presence of 
greatly increased iron stores suggests that the reticulo-endothelial hyperplasia is 
accompanied by abnormal iron retention by macrophages, typical of anemia of chronic 
diseases. This may limit the marrow response to hemolysis. In Mediterranean 
population  a  very  rapid  onset  of  anemia  with  hemolysis  is commonly  
observed(39). Nutritional status is also factor for anemia as the study shows the 
prevalence of anemia shows that among 403 VL patients 29.3% mildly,31.7% 
moderately and 39% severely malnourished and nearly half of the patients also infected 
with one or more intestinal parasite ,among this 21% accounted hook warm(11). 
VL with malaria co-infection more severe symptoms compared to mono-infected 
patients, however had a similar prognosis, if possibly early diagnosis of malaria as a 
result of systematic testing(40).Emergence of drug resistance further complicates the 
treatment of visceral leishmaniasis. It is common among HIV/VL for complete cure of 
patients will require longer hospitalization. generally the overall improvement  will be 
delayed(41). Iron deficiency anemia (inadequate amount of red blood cells caused by 
lack of iron) is highly prevalent in less-developed countries but also remains a problem 
in developed countries. Iron is required for hemoglobin synthesis; if iron stores are low 
due to reasons ranging from malabsorption , RBC production is unable to keep up with 
the body’s needs(42).VL patients with severe anemia often require blood transfusion 
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before starting chemotherapy due to weakness, such interventions to manage anemia 
may be used for VL patients to improve their quality of life  and to increase their 
tolerance to chemotherapy(14). 
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1.3 Conceptual framework 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Conceptual framework adopted from literature review 
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1.4. Justification of the study  
Anemia is one of the major clinical presentations of visceral leishmaniasis, and the 
mean hemoglobin level is 7.2gm/dl(14). It is known that anemia in VL patients can be 
due to either nutritional deficiency or suppression of erythropeosis due to the 
sequestration of the parasite in bone marrow and spleen.  The management is 
according to the severity of problem. If the problem is sever, blood transfusion will be 
given otherwise Iron and folic acid will be supplemented in addition to high iron and 
vitamin content food.  
The national leishmaniasis treatment guideline also recommends iron and vitamin 
supplementation. However most of visceral leishmaniasis treatment centers did not 
supplement including University of Gondar Hospital Leishmaniasis Research and 
Treatment Center except Abdurafi MSF Holland Kala-azar treatment center.  
We have observed hematological improvement within two weeks and complete 
recovery occurs within 4 to 6 weeks in both treatment centers. However, there is no 
evidence whether iron and folic acid has better treatment outcome of anemia or not 
among visceral leishmaniasis patients.  
Therefore this study will be valuable for local decision maker on the treatment site as 
well as for researcher to be an input of other studies, specifically to standardize 
management of anemia among visceral leishmaniasis throughout the country. 
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2. Objective  
2.1. General Objective 
  To assess change in hemoglobin and its determinants among Visceral 
leishmaniasis patients with and without iron–folic acid  supplementation in 
Northwest Ethiopia ,2017 
2.2. Specific objective  
 To compare  changes of hemoglobin among VL patients with and without iron –
folic acid  supplementation  
 To identify determinant factors in change of hemoglobin among VL patients  
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3. Methods 
3.1. Study design and Period  
 Institution based retrospective cohort study was conducted from March to April/2017 by 
reviewing VL patient charts from Jan /2015 to Dec/2016. 
3.2. Study setting  
The Northwest Ethiopia is the high burden VL endemic areas. Addis zemen, Metema, 
Quara, West Armachiho, Humera, bordering Sudan and Eritrea are the main endemic 
foci for visceral leishmaniasis. Accounting more than 60% of case burden in the country 
(43). Sesame is the main cash crop in these regions. Thousands of young migrant 
workers travel   from non endemic area to the endemic foci, Due to the poor economic 
status and high prevalence of  human immune deficiency virus (HIV) in the region, 
many of them have suppressed immunity and can acquire the   disease easily.  
The study was conducted in Northwest Ethiopia at the Leishmaniasis Research and 
Treatment Center (LRTC) of University of Gondar Hospital (UOG) and at the Abdurafi 
Health Center. Both are the largest as well as specialized leishmaniasis diagnosis and 
treatment centers in the region and are supported by the non-governmental 
organizations Drugs for Neglected Diseases initiative (DNDi) and Médecins sans 
Frontières (MSF) respectively. Each center has its own admition ward, pharmacy, 
laboratory where hematological and clinical chemistry are done routinely. Patients 
present to the centers either directly by themselves or are referred from other health 
institution.  
Admitted patients with VL in both treatment centers are routinely evaluated and the 
findings are documented in their respective chart.  The patient’s hematology, blood 
chemistry and other investigations are determined as part of other clinical evaluation 
modalities. Nutritional assessment, such as weight, and Body mass index are measured 
weekly and at admission and discharge, respectively.  
In Abdurafi MSF Holland kala-azar treatment center in addition to VL management 
almost all patients are supplemented with Iron and folic acid for anemia management, 
and therapeutic milk (F100) or Plumpynut for management of malnutrition based on the 
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severity of the nutritional status in addition to high protein diet. But in LRTC only high 
protein diet like egg and milk given according to the severity.  MSF treatment center has 
a well established database system for archiving patient information whereas LRTC has 
a chart archiving room to keep it safely. Hence, data from both treatment centers can be 
retrieved easily.  
3.3. Source population  
 All patients treated for VL at UOG Hospital and Abdurafi MSF Holland Leishmaniasis 
Treatment Centers was the source population.  
3.4. Study population  
The study population was all VL patients treated at UOG Hospital and Abdurafi MSF 
Holland Leishmaniasis Treatment Centers from 2015 to 2016 
3.5. Sample size determination  
The sample size was calculated by using mean estimation formula with an assumption 
of 95% level of confidence, 80% power, a 1∶1 exposed: non exposed ratio from pilot 
study of Abdurafi MSF Holland and UOG Hospital Leishmaniasis Treatment Centers 
and the mean hemoglobin of non exposed and exposed group were 10.5 and 9.9, ±2.6 
respectively. 
𝑁2 = (𝑍𝛼
2⁄
+ 𝑧𝛽)
2
  𝛿2(1 + 1 𝐾⁄ )
𝜀2
 
 N=sample size, δ=Variance,   K=ratio of n1 to n2, α= confidence level,    β=power 
ε=clinically meaningful mean difference of the two groups 
N2 =(1.96+0.842)2  (2.6)2(1+1/1)    =178,  N1=178 
            (10.5-9.9) 2 
The total sample size will be 356 adding 10% for missing data and the final total 
minimum sample size will be 392. But we have decided to include all the study 
population who fulfill the inclusion criteria to increase the power. 
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3.6. Variables of the study  
3.6.1. Dependent variables 
 Hemoglobin (change of hemoglobin )  
3.6.2 Independent variables  
Socio-demographic  factors, age, sex and residency and hematological and biochemical 
assessment, clinical presentation of visceral leishmaniasis like fever, weight loss, 
spleenomegally, loss of appetite, cough,  bleeding and  bilateral leg edema were   
considered as independent variable. 
Nutritional status, concomitant disease like malaria, tuberculosis, kidney disease, liver 
disease, intestinal parasite, duration of illness, and iron-folate supplementation were 
also considered as independent variable.   
3.7. Inclusion and exclusion criteria  
3.7.1 Inclusion criteria 
Visceral leishmaniasis patients age greater than or equal to 18 years and completed 
anti-leishmaniasis treatment from 2015 to 2016 were included in the study   
3.7.2. Exclusion criteria 
Visceral leishmaniasis patients with HIV co-infection, patients transfused with blood, 
pregnant women, and prolonged hospitalization of more than 20 days and discharged 
before 15 days of VL treatment were excluded.   
3.8. Operational definitions  
Change of hemoglobin means either increase or decreases a unit of g/dl from the 
baseline of patient’s hemoglobin.   
Anemia can be classified by using   the   level   of hemoglobin in g/dl.  Hemoglobin 
status between12–16 g/dl and 13–17 g/dl were considered as normal for female and 
male patients, respectively. Mild anemia for females and male patients ranged between 
11–11.9 g/dl and 11–12.9 g/dl hemoglobin, respectively. For both sexes with 
hemoglobin level of 8–10.9 g/dl and <8g/dl were considered as moderately anemic and 
severely anemic, respectively(11).  
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Body mass index Means weight divided by height in meter square and 18.5 to 24.5; 
normal, 17 to 18.49; mild, 16 to 17 moderate less than 16; severe malnutrition.  
Splenomegally is defined as palpable spleen below the costal margin which was 
measured along the line of growth in centimeter.  
3.9. Data collection procedures  
Data extraction tool was prepared and the data collectors were the staffs working in 
both organizations. They were experienced in data management and handling and 
trained in Good Clinical Practice (GCP). Four data collectors and 2 supervisors were 
participated on both treatment sites and training was given for them about the overall 
purpose of the study and was exercised or demonstrated. During the study period the 
supervisors as well as principal investigator supervised and correction was given for any 
unclear things for data collectors.  
3.10. Data processing and analysis  
The data was entered to EpiData software version 3.1 and it was cleaned, and 
transformed to Stastical Package for Social Science (SPSS) version 20 for data 
management and analysis. It was analyzed using independent sample T test for 
comparison of change of hemoglobin from baseline to end of VL treatment with and 
without iron- folic acid supplementation. And we used simple linear regression model 
each possible factors to the outcome variable change of hemoglobin. Variables p-value 
<0.2, was further analyzed in backward multiple linear regression model after checking 
the model fitness and fulfilling model assumptions  and finally the data presented in the 
form of tables and texts . Ninety five percent (95 %) Confidence level was used and p-
values less than 0.05 considered as statistically significant. 
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4. Ethical considerations 
Ethical approval was obtained from the Institute of public health University of Gondar 
Research Ethics Committees. Permission was also obtained from LRTC in University of 
Gondar hospital and MSF Holland in Netherlands to review the records. Data extraction 
tool was used; patients name was not listed and the confidentiality of patient’s data kept 
and at the end of the study the data collection tool was kept locked.  
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5. Result 
5.1. Socio–demographic and clinical characteristics 
A total of 602 VL patients’ chart from 2015 - 2016 were reviewed. Almost equal number 
of cases of VL were included at each study site; three hundred (49.8%) in UOG Hospital 
and 302(50.2%) in Abdurafi MSF Holland leishmaniasis treatment centers. The vast 
majority were male (>99.5%) with the mean age of 24.5(±6.2) in both treatment groups. 
Nearly half of the patients 299 (49.7%) were migrant workers .Whereas the remaining 
303(50.3%) were permanent   resident in the endemic foci of visceral leishmaniasis. 
The median (IQR) of duration of illness in both iron and folic acid supplemented (IFS) 
and unsupplemented (IFUS) groups were 4(2-5) and 4(4-8) weeks respectively. 
We have assessed the clinical presentation of both iron and folic acid exposed and 
unexposed groups of baseline information. This shows that almost all things are 
equivalent. The main clinical presentation of VL both IFS and IFUS group of patients 
were summarized in the table below [table 1].  Among IFS fever was 296 (97.7%), loss 
of appetite, 269(88.8%) weight loss 244(80.5%) and splenomegally 
292(96.4%).Similarly the IFUS group also fever was 287(96%), weight loss 244(80.5%), 
loss of appetite 274(91.6%), splenomegally 286(95.7%). The baseline and end of 
treatment median (IQR) spleen size IFS group were 7(4-10) and 2(0-5) respectively. 
Whereas the IFUS group similarly the median (IQR) of spleen size were 8(6-12) and 
4(0-6) respectively as well. With regards to nutritional status of VL patients, the overall 
prevalence of malnutrition in both IFS and IFUS groups were 221(72.9%) and 265(89%) 
respectively. Of which 52(17.2%) and 122(40.8%) in IFS and IFUS groups were 
severely malnourished respectively [Table-1]. 
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Table 1   Scio-demographic and baseline clinical characteristics of visceral 
leishmaniasis patients from 2015-2016 in university of Gondar Hospital and Abdurafi 
MSF Holland leishmaniasis treatment centers 
Variables  Iron and folic acid N=602 
Supplemented (n=303) 
 Frequency (%) 
Unsupplemented(n=299) 
Frequency (%) 
sex    
   Male     
   Female 
301(99.3) 
2(0.7) 
298(99.7) 
1(0.3) 
Age in years    
    18-27 
    28-37 
    38-47 
    48-57 
   Mean((±SD*) 
238(78.5) 
47(15.5) 
12(4) 
6(2) 
24.43(6.15) 
218(72.9) 
64(21.4) 
16(5.4) 
1(0.3) 
24.75(6.0) 
Residency    
      Stable residents 
      Migrant workers                                                            
254(83.8) 
49(16.2) 
49(16.4) 
250(83.6) 
Treatment site    
        **LRTC 
      ***  MSF 
0 
303(100) 
299(100) 
0 
Duration of illness(weeks)    
      ≤ 6weeks 
      >6weeks 
      Median(IQR****) 
230(75.9) 
73(24.1) 
4(3) 
192(64.2) 
107(35.8 
4(4) 
Fever >2Weeks    
     Yes 
      No 
296(97.7) 
7(2.3) 
287(96) 
12(4) 
Abdominal swelling   
   Yes 
   No 
196(64.7) 
107(35.3) 
116(38.8) 
183(61.2) 
Easy fatigability    
     Yes 
     No 
194(64) 
109(36) 
179(59.9) 
120(40.1) 
Repeated attack of malaria   
    Yes 
    No 
35(11.6) 
268(88.4) 
119(39.8) 
180(60.2) 
Weight loss   
     Yes 
     No 
244(80.5) 
59(19.5) 
274(91.6) 
25(8.4) 
Loss of appetite    
     Yes 
     No 
269(88.8) 
34(11.2) 
270(90.3) 
29(9.7) 
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Ee *standard deviation, **Gondar leishmaniasis research and treatment center, ***medicine sans frontiers (Abdurafi), 
****inter quartile range, ***** bilateral pedal pitting edema, ******body mass index 
We have assessed the diagnostic mechanism of both treatment centers, the majority of 
patients 283(93.4%) in Abdurafi MSF Holland were diagnosed by serological and using 
case definition. Whereas in LRTC 269(90%) were diagnosed by parasitological 
examination. Among this 220(73.6%) was tissue aspiration from spleen and the 
remaining 49(16.4%was from bone marrow aspiration.  The majority of patients IFS and 
IFUS groups 215(71%) and 269(90%) were treated with combination of sodium 
stibogluconate and paramomycine injection for 17 days respectively. In addition to VL 
treatment and IFS, 205(67.7%) were supplemented with therapeutic nutrition 
Nasal bleeding 
         Yes 
         No 
167(55.1) 
136(44.9) 
68(22.7) 
231(77.3) 
Diarrhea   
       Yes 
       No 
41(13.5) 
262(86.5) 
36(12) 
263(88) 
Cough   
     Yes 
      No 
157(51.8) 
146(48.2) 
143(47.8) 
156(52.2) 
Pale conjunctiva   
    Yes 
   No  
230(75.9) 
73(24.1) 
198(66.2) 
101(33.8) 
Splenomegally    
   Yes 
    No  
292(96.4) 
11(3.6) 
286(95.7) 
13(4.3) 
Hepatomegally    
    Yes 
    No  
61(20.1) 
242(79.9) 
72(24.1) 
227(75.9) 
Lyphadnopathy    
     Yes 
     No  
11(3.6) 
292(96.4) 
7(2.3) 
292(97.7) 
Jaundice    
     Yes 
     No  
20(6.6) 
283(93.4) 
26(8.7) 
273(91.3) 
***** BLPP edema   
       Yes  
       No  
38(12.5) 
265(87.5) 
67(22.4) 
232(77.6) 
******Baseline BMI(kg/m
2)
   
       Normal  
       Mild malnutrition  
       Moderate malnutrition  
       Severe malnutrition  
82(27.1) 
96(31.7) 
73(24.1) 
52(17.2) 
33(11) 
67(22.4) 
76(25.4) 
122(40.8) 
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(Plumpynut and f100). At the end of treatment 294(97%) and 295(98.7%) of IFS and 
IFUS groups were declared initial cure respectively, while the remaining was treatment 
failures [table-2].  
Table 2 Diagnoses, management and concomitant disease or complication of visceral 
leishmaniasis from 2015-2016 in University of Gondar Hospital and Abdurafi MSF 
Holland leishmaniasis treatment centers 
Characteristics(variables) Iron and folic acid 
Supplemented 
Frequency (%) 
Unsupplemented  
Frequency (%) 
Diagnosis   
       Serological and /or clinical 
       Parasitological 
283(93.4) 
20(6.6) 
30(10) 
269(90) 
Site of aspiration   
        Spleen 
       Bone marrow 
17(5.6) 
3(1) 
220(73.6) 
49(16.4) 
Anti leishmaniasis given   
        *SSG+PM 
        Ambisome 
215(71) 
88(29) 
269(90) 
30(10) 
Initial treatment outcome   
       Initial cured 
      Failure 
294(97) 
9(3) 
295(98.7) 
4(1.3) 
Nutrition support(**PPN,F100)   
    Yes 
     No 
205(67.7) 
98(32.3) 
3(1) 
296(99) 
Concomitant diseases/complications   
    Current malaria 
    Pneumonia 
    Ear infection 
    Intestinal parasite 
    Skin fungal infection  
    Pancreatitis 
    Sever Neutropinia (<500 neutrophils 
count) 
    ***Others 
15(5) 
83(27.4) 
13(4.3) 
58(19.1) 
3(1) 
2(0.7) 
65(21.5) 
 
25(8.3) 
 
31(10.4) 
42(14) 
12(4) 
64(21.4) 
19(6.4) 
10(3.3) 
43(14.4) 
 
12(4) 
*sodium stibogluconate +Paramomycine, **Plumpynut, therapeutic Milk ***ascities Hyper active spleenomegally, 
upper respiratory infection, acute kidney injury, oral candidacies, snake bite, hemorrhoid, sexual transmitted 
infection and tooth infection  
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5.2. Hematological profile of baseline and end of treatment of VL patients  
This research evaluated the baseline and end of treatment hematological profile of 
patients in both treatment centers. The overall prevalence of anemia was 303(100%) 
and 300(99%) at the baseline and end of treatment among IFS group respectively. It 
looks no deference from baseline to end of treatment. But severe anemia at the 
baseline was 147(48.5%) and 90(29.7%) at the end of treatment. This shows that there 
was Improvement across the degrees of anemia. Similarly, the overall prevalence of 
anemia among IFUS groups was 291(97.4%) and 278(93%) at baseline and end of 
treatment respectively. Here also severe anemia was 107(35.8%) at the baseline and 
improved to 34(11.4%) at the end of VL treatment. Therefore this showed us 
improvement of hemoglobin from severe condition to moderate as well mild anemia. We 
have observed the improvement of other hematological parameters, like the mean (SD) 
white blood cells from 1.98(± 1.4) to 3.4(±1.5) times 103/µl in IFS group and 2.3(±1.3) to 
3.8(±1.4) in IFUS group.  The median (IQR) platelet count of VL patients improved from 
85(60-127) to190 (153-253) times103/µl among IFS group. Whereas the IFUS group 
was 76(46-114) and 228(154-306) times 103/µl at baseline to end of treatment 
respectively [table 4]. 
Table 3 Comparison of level of anemia from baseline from baseline to end of VL 
treatment with and without iron and folic acid supplementation  
Level of Anemia  Iron and folic acid supplementation(N=602) 
Supplemented(n=303)  Un-supplemented (n=299) 
Baseline  End of Tx Baseline  End of Tx 
Mild anemia  12(4%) 29(9.6%) 43(14.4%) 96(32.1%) 
Moderate anemia   144(47.5%) 181(59.7%) 141(47.2%) 148(49.5%) 
Severe  anemia  
Over all prevalence  
147(48.5%) 
303(100%) 
90(29.7%) 
300(99%) 
107(35.8%) 
291(97.4%) 
34(11.4%) 
 278(93%) 
 
20 
 
Table 4 Laboratory as well as physical characteristics of VL patients from 2015-2016 in 
University of Gondar Hospital and Abdurafi MSF Holland leishmaniasis treatment 
centers between iron and folic acid supplemented and unsupplemented groups  
WBC=white blood cell, IQR =Interquartile range, SD= standard deviation, MCV =mean cell Volume, SGPT =serum glutamate 
Pyruvate Transaminase, SGOT=serum glutamate oxalate Transaminase, BUN = blood urea nitrogen, Tx=treatment No anemia, 
mild, moderate and severe anemia means hemoglobin >13g/dl,11-12.9g/dl, 8-10.9 and <8g/d respectively (WHO classification 
criteria 
5.3 Comparison of change of hemoglobin between two groups  
Comparison of change of hemoglobin of VL patients with and without iron-folic acid 
supplementation is summarized in [table-5]. The base line mean (SD) hemoglobin of 
303 (50.3%) of VL patients supplemented with iron folate was 8(±1.7), whereas it was 
8.99(±1.67) g/dl at the end of treatment. Similarly, the mean (SD) of hemoglobin of VL 
patients 299(49.7%) not supplemented with iron-folic acid was 8.77(±2.18) and 
10.38(±1.85) g/dl for baseline and end of treatment, respectively. Therefore, the change 
of mean (SD) hemoglobin with and without iron-folate supplementation from end of 
treatment to the baseline was 0.99(±1.64) and 1.61(±1.88) g/dl, respectively with the p-
value of <0.0001.This means that, there is statistical significant difference between iron-
folate supplemented and un-supplemented with the outcome variable of change of 
hemoglobin [table 5]. 
Variables  Iron and folic acid 
Supplemented group unsupplemented group 
WBC(x10
3
/µl)   
         Baseline mean(SD) 
         End of Tx mean(SD) 
1.98(±1.4) 
3.4(±1.5) 
2.3(±1.3) 
3.8(±1.4) 
Platelet count(x10
3
/µl)   
         Baseline Median(IQR) 
         End of Tx Median(IQR) 
85(60-127) 
190(153-253) 
76(46-114) 
228(154-306) 
Mean cell volume (%)   
          Baseline Mean(SD) 
         End of Tx m mean(SD) 
79.2(±7.3) 
81(±9) 
82(±9.3) 
85.5(±8.56) 
Spleen size(centimeter)   
       Baseline Median(IQR) 
      End of Tx Median(IQR) 
7(4-10) 
2(0-5) 
8(6-12) 
4(0-6) 
Body mass index(Kg/m
2 
)   
       Baseline Mean(SD) 
      End of Tx  mean(SD) 
17.4(±1.6) 
17.9(±1.8) 
16.5(±1.6) 
16.89(±1.64) 
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 Table 5 Comparison of change of hemoglobin with and without iron-folic acid 
supplementation  
Variables Hemoglobin(g/dl) 95%CI of the 
mean 
difference 
P-value 
Iron- folate 
supplementation 
N Baseline 
mean(SD) 
End of 
treatment 
mean(SD) 
change of 
mean(SD) 
Mean 
difference 
Lower upper  
    Yes 
    No 
303 
299 
8.0(±1.7) 
8.77(±2.18) 
8.99(±1.67) 
10.38(±1.85) 
0.99(±1.64) 
1.61(±1.88) 
 
0.62 
 
0.34 
 
0.90 
 
<0.0001 
 
*Independent  sample  T test done , HGB= hemoglobin, SD =standard deviation , N =sample size 
 
5.4. Determinant factors for the change of hemoglobin  
The determinant factors for change of hemoglobin from baseline to end of treatment 
were assessed using linear regression model. The independent variables with P- value 
< 0.05 were further analyzed using the backward multiple linear regression model to 
identify the predictor variables. Combination therapy (SSG+PM) was positively 
associated with p-value of less than 0.0001. Whereas age (p=0.001), nasal bleeding 
(P=0.035), baseline white blood cells (p=0.002), baseline hemoglobin (p<0.0001), end 
of treatment spleen size and iron-folic acid supplementation were negatively associated 
with the p-value less than 0.0001 at 95% confidence level [table-6]. 
Based on this analysis result, baseline spleen size, baseline and end of treatment body 
mass index, did not show statistical significant association with the outcome variable 
(change of hemoglobin). 
 
 
 
 
 
 
 
22 
 
 
 
Table 6 Determinant factors for change of hemoglobin among visceral leishmaniasis 
patients  
Independent 
 variables ( factors) 
(B)Coefficients/std-error  95%(CI for B) P-value 
Lower Upper 
Constant  6.866/0.397 6.085 7.646 < 0.0001 
*SSG+PM(anti-leishmaniasis )  0.710/0.15 0.416 1.005 <0.0001 
Age -0.030/0.009 -0.049 -0.012   0.001 
 Nasal bleeding -0.261/0.123 -0.502 -0.019   0.035 
Baseline **WBC -0.139/0.044 -0.226 -0.052   0.002 
Baseline ***HGB -0.513/0.031 -0.574 -0.452 <0.0001 
End of *****Tx spleen size -0.059/0.015 -0.088 -0.029 <0.0001 
Iron-folic acid supplementation -0.574/0.163 -0.895 -0.253 <0.0001 
Baseline platelet count  0.001/0.001 -0.001  0.003   0.227 
Baseline spleen size   0.024/0.020 -0.016  0.064   0.247 
Baseline body mass index  0.006/0.040 -0.072  0.085   0.872 
*sodium stibogluconate and paramomycine, ** white blood cells, ***hemoglobin, ****Treatment  
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6. Discussion  
Anemia is the most common public health problem, it has global prevalence of 32.9% 
and caused 68.36 million years lived with disability. Iron deficiency is commonly 
assumed to cause half of all cases of anemia(2). However the impact of iron 
intervention is lower in population with both with high burden of anemia and very high 
inflammation exposure as well as its absorption is restricted in the presence of 
inflammation. The consequences of anemia Leads physical and mental disability in 
children and in the elderly, along with reduction in working capacity in adults(3).The 
base line and end of treatment mean (SD) hemoglobin of VL patients supplemented 
with iron folate was of 8(±1.7) and 8.99(±1.67) g/dl, respectively. Similarly the mean 
(SD) hemoglobin of VL patients 299(49.7%) not supplemented with iron- folic acid was 
8.77(±2.18) and 10.38(±1.85) g/dl for baseline and end of treatment respectively. This 
study illustrated that there was a significant variation in the change of the mean 
hemoglobin level at the beginning and end of treatment of VL among the patients who 
took and did not  receive iron-folate supplementation (0.99(±1.64) and 1.61(±1.88)g/dl 
respectively with P-value of <0.0001 at 95% confidence level. The study conducted in 
Sudan among those who did not receive Iron and folic acid the mean change of 
hemoglobin was 3.1g/dl which is higher than ours. This might be due to low sample size 
in Sudan(22).  The variation could be attributed by iron supplementation.  There is no 
evidence whether iron directly affects the change of hemoglobin but experimental 
studies showed that leishmania parasite directly used iron for survival and growth(16). 
Therefore iron supplementation might create conducive environment for the parasite.  
Whereas baselines mean hemoglobin difference might be due the hematology analyzer 
machine as well as the reagent used. 
As Backward linear regression model indicates, that those who were treated with 
combination of sodium stibogluconate and paramomycine, the average change of 
hemoglobin was increased  by  0.710 at  95% CI(0.416,1.005) with the p-value <0.0001 
relatively with who treated with Ambisome keeping the other factors constant .which is 
consistent the study conducted in Sudan  that SSG significantly increase the 
hemoglobin(22). 
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This could be due to the treatment directly kill the parasite inside phagolysosome by 
inhibiting trypanothoine reductase (an enzyme that recycle oxidized trypanothoine to 
keep the trypanothoine in reducing state and the  hematopoietic  were suppressed with 
the parasite, As the result of the treatment the hemoglobin start to increased(41). The 
other possible reason might be those who were treated with Ambisome were relatively 
low in number. 
Age of VL patients is main predictors ,here in this study  when age increased in year the 
average change hemoglobin decreased  by 0.03 at 95% CI (-0.049, -0.012) with the p-
value of 0.001 keeping other factors constant. It is consistent with the study conducted 
in East Boston(44). 
The size of spleen at the end of VL treatment and average change of hemoglobin were 
inversely proportional and the coefficient was -0.059 at 95% CI (-0.088, -0.029) with the 
p-value of <0.0001.This might be due to sequestration and destruction of red blood cells 
in enlarged spleen and bone marrow(12).  
Visceral leishmaniasis patients those had nasal bleeding decreased the average 
change of hemoglobin by 0.261 at 95%Cl (-0.502, -0.019) with the p-value 0.035 
Keeping other factors constant. This could be due to very low platelet count as the 
result of bone marrow suppression. So that the improvement of hemoglobin might not 
be the same as to those did not have nasal bleeding. 
Iron and folic acid supplementation of VL patients decreased the average change of 
hemoglobin by 0.574 at 95% CI (-0.895, -0.253) with the p-value <0.0001by keeping the 
other factors constant. As to my best knowledge there is no study done on Iron-folate 
among visceral leishmaniasis patients to compare our findings, however there are 
experimental studies that showed us the effect of iron among leishmania parasite in vivo 
on animal model as well as in vitro by preparing the culture media. Eventhough there 
are studies that support our findings, there are also contradictors. The study conducted 
in Belgium was suggested that adequate   supply   of iron   is needed   for   the   life 
cycle of leishmania parasite. The authors investigated  the effect  of iron deprivation  on  
the growth  of promastigotes stages of leishmaniasis  in  vitro  using  an  iron  chelating  
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approach. All chelators tested reduced the rate of promastigotes multiplication in a 
dose-dependent fashion. Finally they suggested that  iron  depletion  may  be  an  
effective mechanism  against  leishmania  infection. And also iron ions are crucial for 
anti-oxidizing function and other metabolic reaction of the parasite which makes the 
replication favorable(16). 
A study conducted in Portugal  the  mammalian  stage  of  Leishmania (amastigotes ),  
must  acquire  iron  from  molecules  accessing  the macrophage parasitophorous 
vacuole (PV) where they inhabit. The molecules include non-heme and heme-bound 
forms of iron. Here the authors demonstrated that, Leishmania amastigotes are also 
capable of exploiting iron from hemin and hemoglobin for nutritional purposes. 
Moreover, evidence is presented that a ligand at the surface of amastigotes binds 
hemin with high-affinity(15).Leishmaniasis is Intracellular pathogens which employ 
several strategies for iron acquisition from host macrophages for survival and growth, 
whereas macrophage resists infection by actively sequestering iron. Here, instead  of  
allowing  macrophage  to sequester  iron,  protozoan  parasite  Leishmania donovani 
(LD) uses a novel strategy to manipulate iron uptake mechanisms of the host and 
utilizes the taken up iron for its intracellular growth. Therefore, intracellular LD directly 
scavenges iron from labile iron pool of macrophages(45).In contrary another study 
conducted in Portugal, the effects of iron supplementation or deprivation on the growth 
of L.infantum. The authors confirm that dietary iron deficiency did not affect the 
protozoan growth, whereas iron overload decreased its replication in the liver and 
spleen of a susceptible mouse strain(17).  
7. Limitation of the study  
This research used secondary data, as the result, did not assess the income as well as 
dietary history of patients and which it might reduce the validity. The other limitation was 
unable to show the effect of iron and folic acid on the change of hemoglobin separately. 
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8. Conclusion  
Anti leishmaniasis treatment of SSG and pm, age, nasal bleeding, baseline white blood 
cells, baseline hemoglobin and iron and folic acid supplementation were determinants of 
change of hemoglobin. 
 Iron-folate supplementation has no significant effect on the improvement of VL patient’s 
hemoglobin level, rather it delays. However, it does not mean that there is no iron- folate 
deficiency.  Probably the leishmania parasite might use iron for survival and growth.  
9. Recommendation  
For clinician: Combination of SSG and PM for the management of VL patients had 
direct relationship with the change of hemoglobin which means that treatment of VL 
alone boost up the hemoglobin level. Whereas age of the patients, baseline WBC, 
baseline hemoglobin, end of treatment spleen size, nasal bleeding and Iron and folic 
acid supplementation negatively affects the improvement of hemoglobin. Therefore we 
recommend for clinicians to focus and prompt management on the above determinants 
for the better improvement of anemia.   
For researcher: Here in this study we couldn’t show the effect of iron and folic acid 
separately. Therefore we recommend scholars to investigate and explore more on the 
effect of each as well as the appropriate time of supplementation among VL patients 
with randomized control study design. 
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Annex I: Case report format for data collection  
Visceral Leishmaniasis data collection tool for Change of hemoglobin among VL patients with and 
without iron-folate supplementation for those who were admitted and treated for VL and fulfill the 
inclusion criteria from Jan/2015 to Dec /2016. 
Investigator:-Tadele Mulaw  
Address: -    Phone: +251 928505293 
                   Email:  tadelemulaw@yahoo.co.uk 
1. Scio-demographic characteristic of the patient                                                                                    
101 Patient ID __________ Date ____________(dd/mm/yyyy) 
 
102 Age _____________  
103 Sex 1. Male 2.  Female  
104   Residency 1. Migrant worker 2. permanent resident  
105 Treatment site 1. LRTC 2. MSF 
 2. Baseline history and physical examination  
code     Clinical history  Yes  No  Code Physical examination  Yes  No  
201 Duration of illness(in     
weeks)_____________ 
NA NA 212 Pale conjunctiva     
202  Fever more than 2 wks   213 Splenomegally    
 203  Abdominal swelling    214 Hepatomegally   
204 Easy Fatigability    215 Lyphadnopathy    
205 Repeated attack of malaria   216 Jaundice (icteric sclera)   
206 Weight loss   217 Oedema(bilateral pitting pedal)     
207 Loss of appetite        
208 Nasal Bleeding        
209 Diarrhea        
210 Cough        
211 Yellow discoloration of eyes        
3.  Clinical evaluation (Hematological and Biochemical laboratory) findings  
Code Category Base 
line  
End of 
treatment 
Code Category  Baseline  End of 
treatment  
301 WBC (x10
3/µl
   310 Weight(Kg)   
302 Hemoglobin (g/dl)   311 Height (cm)  NA 
303 Platelet(x10
3 
/µl
  
)   312 BMI(kg/m
2
)   
304 MCV (%)    313 Spleen size(cm)   
305 Neutrophile count(No)       
306 SGPT(U/L)       
307 SGOT(U/L)       
308 Creatinine (mg/dl)         
309 BUN(Mg/dl)       
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4. Diagnosis and management of VL  
Code Methods of diagnosis  1. Serology and/ or clinical  2.   Parasitological  
401 If parasitological, where is site? 1. SA                  2. BM 3.  Lyphnode  
402 Anti-leishmaniasis given   1. SSG+Pm 2. Ambisome  
403 Initial treatment outcome  1.Initial cured 2.   failure 
404 Iron-folate  supplementation  1. Yes 2. No 
405 Plumpynut given  1. Yes 2.  No 
5. Concomitant disease  
Concomitant disease Yes No 
501 Malaria   
502 If “yes “what type of malaria? 1. Pf      2. Pv              3. Mixed 
503 Pneumonia   
504 Ear infection    
505 Intestinal parasites    
506 Skin fungal infections    
507 Pancreatitis(physician Judgment)    
508 Viral hepatitis (screened viral marker)   
509 Neutropinia (neutrophile  count<500)   
510 Tuberculosis(any)   
511 Others (specify)  
 
NB:  inclusion criteria 09 
 Age ≥18 years  and completed treatment 
Exclusion  
 HIV/VL 
 Pregnant mother 
 Stayed less than 15 days or greater than 20 days 
 Blood transfused 
 
Data collector signature _______________    supervisor signature __________ 
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